脑组织胆固醇稳态失衡对阿尔茨海默病的影响及其分子机制研究

doi:10.3969/j.issn.1672-6731.2022.03.013

摘要/Abstract

摘要： 阿尔茨海默病的发病机制主要包括神经元和突触减少、细胞外β-淀粉样蛋白（Aβ）沉积、神经炎性斑（NPs）形成和细胞内tau蛋白过磷酸化，导致神经原纤维缠结（NFTs）形成。其中，神经炎性斑和神经原纤维缠结形成与脑组织胆固醇稳态失衡密切相关，提示后者在阿尔茨海默病的发生发展中起决定作用。本文综述脑组织胆固醇稳态失衡对阿尔茨海默病的分子调控机制。

关键词: 阿尔茨海默病, 胆固醇, 分子生物学, 综述

Abstract: The pathogenesis of Alzheimer's disease (AD) mainly includes the decrease of neurons and synapses, the deposition of the extracellular β-amyloid protein (Aβ), the formation of neuritic plaques (NPs) and neurofibrillary tangles (NFTs) caused by intracellular tau protein hyperphosphorylation. NPs and NFTs are closely related to the brain cholesterol homeostasis imbalance, suggesting that normal brain cholesterol homeostasis may play a decisive role in the development of AD. This paper reviews the molecular regulation mechanism of brain cholesterol homeostasis imbalance in AD.

Key words: Alzheimer disease, Cholesterol, Molecular biology, Review

王苏苏, 吴美琴, 裴尚飞, 颜崇淮. 脑组织胆固醇稳态失衡对阿尔茨海默病的影响及其分子机制研究[J]. 中国现代神经疾病杂志, 2022, 22(3): 200-204.

WANG Su-su, WU Mei-qin, PEI Shang-fei, YAN Chong-huai. Effects of brain cholesterol homeostasis imbalance on Alzheimer's disease and its related molecular mechanisms[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(3): 200-204.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I3/200

参考文献

[1] Tang X, Zhao W, Lu M, Zhang X, Zhang P, Xin Z, Sun R, Tian W, Cardoso MA, Yang J, Simó R, Zhou JB, Stehouwer CDA. Relationship between central obesity and the incidence of cognitive impairment and dementia from cohort studies involving 5, 060, 687 participants[J]. Neurosci Biobehav Rev, 2021, 130:301-313.
[2] Segatto M, Tonini C, Pfrieger FW, Trezza V, Pallottini V. Loss of mevalonate/cholesterol homeostasis in the brain:a focus on autism spectrum disorder and rett syndrome[J]. Int J Mol Sci, 2019, 20:3317.
[3] Gao P, Ye L, Cheng H, Li H. The mechanistic role of Bridging Integrator 1(BIN1) in Alzheimer's disease[J]. Cell Mol Neurobiol, 2021, 41:1431-1440.
[4] Brenowitz WD, Xiang Y, McEvoy CT, Yang C, Yaffe K, Le WD, Leng Y. Current Alzheimer disease research highlights:evidence for novel risk factors[J]. Chin Med J (Engl), 2021, 134:2150-2159.
[5] Biscetti L, Lupidi M, Luchetti E, Eusebi P, Gujar R, Vergaro A, Cagini C, Parnetti L. Novel noninvasive biomarkers of prodromal Alzheimer disease:the role of optical coherence tomography and optical coherence tomography-angiography[J]. Eur J Neurol, 2021, 28:2185-2191.
[6] Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E:structural insights and links to Alzheimer disease pathogenesis[J]. Neuron, 2021, 109:205-221.
[7] Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol[J]. Proc Natl Acad Sci USA, 2021, 118:e2102191118.
[8] Birolini G, Valenza M, Di Paolo E, Vezzoli E, Talpo F, Maniezzi C, Caccia C, Leoni V, Taroni F, Bocchi VD, Conforti P, Sogne E, Petricca L, Cariulo C, Verani M, Caricasole A, Falqui A, Biella G, Cattaneo E. Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice[J]. EMBO Mol Med, 2020, 12:e12519.
[9] Genaro-Mattos TC, Anderson A, Allen LB, Korade Z, Mirnics K. Cholesterol biosynthesis and uptake in developing neurons[J]. ACS Chem Neurosci, 2019, 10:3671-3681.
[10] Björkhem I, Meaney S. Brain cholesterol:long secret life behind a barrier[J]. Arterioscler Thromb Vasc Biol, 2004, 24:806-815.
[11] Korade Z, Heffer M, Mirnics K. Medication effects on developmental sterol biosynthesis[J]. Mol Psychiatry, 2021.[Epub ahead of print]
[12] Loera-Valencia R, Vazquez-Juarez E, Muñoz A, Gerenu G, Gómez-Galán M, Lindskog M, DeFelipe J, Cedazo-Minguez A, Merino-Serrais P. High levels of 27-hydroxycholesterol results in synaptic plasticity alterations in the hippocampus[J]. Sci Rep, 2021, 11:3736.
[13] Gamba P, Giannelli S, Staurenghi E, Testa G, Sottero B, Biasi F, Poli G, Leonarduzzi G. The controversial role of 24-S-Hydroxycholesterol in Alzheimer's disease[J]. Antioxidants (Basel), 2021, 10:740.
[14] Doria M, Maugest L, Moreau T, Lizard G, Vejux A. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease[J]. Free Radic Biol Med, 2016, 101:393-400.
[15] Petrov AM, Kasimov MR, Zefirov AL. Cholesterol in the pathogenesis of Alzheimer's, Parkinson's diseases and autism:link to synaptic dysfunction[J]. Acta Naturae, 2017, 9:26-37.
[16] Rickman OJ, Baple EL, Crosby AH. Lipid metabolic pathways converge in motor neuron degenerative diseases[J]. Brain, 2020, 143:1073-1087.
[17] Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity:the rotterdam study[J]. J Neurol Neurosurg Psychiatry, 2009, 80:13-17.
[18] Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits[J]. Mol Cell Neurosci, 2010, 45:408-417.
[19] Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice[J]. J Neurochem, 2008, 106:475-485.
[20] Ledesma MD, Martin MG, Dotti CG. Lipid changes in the aged brain:effect on synaptic function and neuronal survival[J]. Prog Lipid Res, 2012, 51:23-35.
[21] Ferris HA, Perry RJ, Moreira GV, Shulman GI, Horton JD, Kahn CR. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism[J]. Proc Natl Acad Sci USA, 2017, 114:1189-1194.
[22] Fukui K, Ferris HA, Kahn CR. Effect of cholesterol reduction on receptor signaling in neurons[J]. J Biol Chem, 2016, 291:15910.
[23] Martin MG, Ahmed T, Korovaichuk A, Venero C, Menchón SA, Salas I, Munck S, Herreras O, Balschun D, Dotti CG. Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents[J]. EMBO Mol Med, 2014, 6:902-917.
[24] Makowski L. The structural basis of amyloid strains in Alzheimer's disease[J]. ACS Biomater Sci Eng, 2020, 6:2498-2505.
[25] Zhang Z, Li XG, Wang ZH, Song M, Yu SP, Kang SS, Liu X, Zhang Z, Xie M, Liu GP, Wang JZ, Ye K. δ-secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer's disease[J]. Mol Psychiatry, 2021, 26:586-603.
[26] Samimi N, Asada A, Ando K. Tau abnormalities and autophagic defects in neurodegenerative disorders; a feed-forward cycle[J]. Galen Med J, 2020, 9:e1681.
[27] Kaur D, Behl T, Sehgal A, Singh S, Sharma N, Bungau S. Multifaceted Alzheimer's disease:building a roadmap for advancement of novel therapies[J]. Neurochem Res, 2021, 46:2832-2851.
[28] Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE:involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro[J]. J Biol Chem, 2005, 280:36815-36823.
[29] Grimm MO, Mett J, Grimm HS, Hartmann T. APP function and lipids:a bidirectional link[J]. Front Mol Neurosci, 2017, 10:63.
[30] Tao PF, Huang HC. Regulation of AβPP glycosylation modification and roles of glycosylation on AβPP cleavage in Alzheimer's disease[J]. ACS Chem Neurosci, 2019, 10:2115-2124.
[31] Alhajraf F, Ness D, Hye A, Strydom A. Plasma amyloid and tau as dementia biomarkers in Down syndrome:systematic review and meta-analyses[J]. Dev Neurobiol, 2019, 79:684-698.
[32] van der Kant R, Langness VF, Herrera CM, Williams DA, Fong LK, Leestemaker Y, Steenvoorden E, Rynearson KD, Brouwers JF, Helms JB, Ovaa H, Giera M, Wagner SL, Bang AG, Goldstein LSB. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer's disease neurons[J]. Cell Stem Cell, 2019, 24:363-375.e9. Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica
[33] Macchi C, M. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels-experimental and clinical approaches with lipid-lowering agents[J]. Eur J Prev Cardiol, 2019, 26:930-949.
[34] Feringa FM, van der Kant R. Cholesterol and Alzheimer's disease; from risk genes to pathological effects[J]. Front Aging Neurosci, 2021, 13:690372. in the brain
[35] Jin U, Park SJ, Park SM. Cholesterol metabolism and its association with Parkinson's disease[J]. Exp Neurobiol, 2019, 28:554-567. Seo J. ApoE4-induced cholesterol
[36] Jeong W, Lee H, Cho S, dysregulation and its brain cell type-specific implications in the pathogenesis of Alzheimer's disease[J]. Mol Cells, 2019, 42:739-746.
[37] Huang B, Song BL, Xu C. Cholesterol metabolism in cancer:mechanisms and therapeutic opportunities[J]. Nat Metab, 2020, 2:132-141.
[38] Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer:rethinking the link[J]. Biomed Pharmacother, 2021, 140:111758.
[39] Duprez DA, Handelsman Y, Koren M. Cardiovascular outcomes and proprotein convertase subtilisin/kexin type 9 inhibitors:current data and future prospects[J]. Vasc Health Risk Manag, 2020, 16:403-418.
[40] Liu M, Wu G, Baysarowich J, Kavana M, Addona GH, Bierilo KK, Mudgett JS, Pavlovic G, Sitlani A, Renger JJ, Hubbard BK, Fisher TS, Zerbinatti CV. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain[J]. J Lipid Res, 2010, 51:2611-2618.
[41] O'Connell EM, Lohoff FW. Proprotein convertase subtilisin/kexin type 9(PCSK9) in the brain and relevance for neuropsychiatric disorders[J]. Front Neurosci, 2020, 14:609.
[42] Apaijai N, Moisescu DM, Palee S, McSweeney CM, Saiyasit N, Maneechote C, Boonnag C, Chattipakorn N, Chattipakorn SC. Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation[J]. J Am Heart Assoc, 2019, 8:e010838.
[43] Bhattamisra SK, Yap KH, Rao V, Choudhury H. Multiple biological effects of an iridoid glucoside, catalpol and its underlying molecular mechanisms[J]. Biomolecules, 2019, 10:32.
[44] Martin MG, Perga S, Trovò L, Rasola A, Holm P, Rantamäki T, Harkany T, Castrén E, Chiara F, Dotti CG. Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro[J]. Mol Biol Cell, 2008, 19:2101-2112.
[45] Suzuki S, Kiyosue K, Hazama S, Ogura A, Kashihara M, Hara T, Koshimizu H, Kojima M. Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development[J]. J Neurosci, 2007, 27:6417-6427.
[46] Spagnuolo MS, Donizetti A, Iannotta L, Aliperti V, Cupidi C, Bruni AC, Cigliano L. Brain-derived neurotrophic factor modulates cholesterol homeostasis and Apolipoprotein E synthesis in human cell models of astrocytes and neurons[J]. J Cell Physiol, 2018, 233:6925-6943.

选择文件类型/文献管理软件名称

选择包含的内容

2 脑组织胆固醇稳态失衡对阿尔茨海默病的影响及其分子机制研究

Effects of brain cholesterol homeostasis imbalance on Alzheimer's disease and its related molecular mechanisms

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 脑组织胆固醇稳态失衡对阿尔茨海默病的影响及其分子机制研究

Effects of brain cholesterol homeostasis imbalance on Alzheimer's disease and its related molecular mechanisms

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价